gene therapy – SRK Analytics

Eli Lilly-Backed Scribe Therapeutics Surges 67% Following $128.7 Million Upsized IPO

On Thursday, Scribe Therapeutics surged 67% during its market debut on the Nasdaq after raising $128.7 million in an upsized initial public offering, signaling renewed investor enthusiasm for early-stage genetic…

Prasenjit Bhowmik July 25, 2026

Emerging Market

UniQure to Seek FDA Approval for Huntington’s Disease Gene Therapy Following Regulatory Dispute

UniQure is pursuing FDA approval for its Huntington's disease gene therapy AMT-130, navigating past regulatory hurdles for this promising treatment.

Prasenjit Bhowmik June 28, 2026